Veru (VERU) Cash from Financing Activities (2010 - 2026)
Veru (VERU) posted quarterly Cash from Financing Activities of $23.4 million for Q4 2025, up 653.49% year-over-year from $3.1 million in Q4 2024, and up 653.49% quarter-over-quarter from -$4.2 million in Q4 2024.
Veru (VERU) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Cash from Financing Activities for 14 consecutive years, with $23.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 653.49% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 653.92% YoY), while the FY2025 annual figure was -$4.2 million, down 111.46% from the prior year.
- Cash from Financing Activities improved to $23.4 million in Q4 2025 per VERU's latest filing, from -$4.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $108.3 million in Q1 2021 and bottomed at -$4.2 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged $11.0 million across 5 years, with a median of $449819.0 in 2021.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 12916.05% — and 2024, when it tumbled 111.42%.
- Veru's Cash from Financing Activities stood at $204427.0 in 2021, then surged by 661.2% to $1.6 million in 2022, then jumped by 2276.06% to $37.0 million in 2023, then plunged by 111.42% to -$4.2 million in 2024, then surged by 653.49% to $23.4 million in 2025.
- Business Quant data shows VERU's Cash from Financing Activities at $23.4 million in Q4 2025, -$4.2 million in Q4 2024, and $3280.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | -51,914.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51,914.00 |
| Jun 30, 2026 | -51,914.00 |
| Dec 31, 2025 | 23.37 Mn |
| Dec 31, 2025 | 23.37 Mn |
| Dec 31, 2024 | -4.22 Mn |
| Dec 31, 2024 | -4.22 Mn |
| Jun 30, 2024 | 3,280.00 |
| Jun 30, 2024 | 3,280.00 |
| Mar 31, 2024 | -150,324.00 |
| Mar 31, 2024 | -150,324.00 |
| Dec 31, 2023 | 36.97 Mn |
| Dec 31, 2023 | 36.97 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 5.17 Mn |
| Mar 31, 2023 | 2.27 Mn |
| Mar 31, 2023 | 2.27 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Dec 31, 2022 | 1.56 Mn |